Last updated: 2026-09-29 23:33:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Silexion Therapeutics Corp. (SLXN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.32, with a market capitalisation of $1.38M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.24 to $42.60. This page covers its latest market performance, valuation, price trends and company information.
$1.38M | |
$0.32 | |
$6,277.50 | |
$0.24 | |
$0.25 | |
252.31M | |
6.41M | |
-- | |
$42.60 | |
$0.24 | |
-- | |
-- |
Silexion Therapeutics Corp. (SLXN) is trading at $0.29 in after-hours trading as of 2026-09-29 23:31:00, up 17.55% ($0.04) from the regular-session close of $0.25.
After-hours trading shows how investors are pricing SLXN after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Silexion Therapeutics Corp. (SLXN) moved from $0.54 to $0.32, representing a decline of 41.00% ($0.22).
The stock traded between $0.24 and $0.63 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 27.21 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.2%
SLXN is currently trading at $0.32, placing it 0.2% of the way from its 52-week low of $0.24 to its 52-week high of $42.60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 13 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Silexion Therapeutics Corp. (SLXN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.